CC
FRTX

Clearline Capital’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Clearline Capital’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-239
Closed -$90K – 57
2019
Q1 		$90K Buy
239
+1
+0.4% +$335 0.05% 39
2018
Q4 		$89K Buy
238
+69
+41% +$27.1K 0.06% 59
2018
Q3 		$73K Buy
+169
New +$71.3K 0.04% 50

Other funds holding FRTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Clearline Capital's FRTX Position: Q2 2019 in Review

Clearline Capital sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q2 2019, closing a stake of 239 shares — an estimated $90K sold.

Clearline Capital first reported a position in FRTX in Q3 2018 and held it in 3 quarters. The position peaked at $90K in Q1 2019. 22 funds tracked by Wall St. Rank hold FRTX as of Q2 2019.

  • Clearline Capital reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Clearline Capital sold 239 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $90K.
  • Clearline Capital first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q3 2018 and held it in 3 quarters.
  • Clearline Capital's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $90K in Q1 2019.
  • 22 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Clearline Capital's 13F filing for Q2 2019, filed 14 Aug 2019.